Background and Aim: Advances in immunosuppression and surgical techniques in liver transplantation (LT) have significantly improved patient outcomes, but donor utilization and access to LT remain a challenge. The past decade has seen significant strides in donor pool expansion with acceptable clinical outcomes, while improved patient selection and advances in the management of chronic liver disease and post-LT complications have promoted better allograft health. This document aims to provide an evidence-based guideline on the management of graft complications, immunosuppression, graft rejection and recurrent disease in adult LT recipients. Methods: A multidisciplinary writing group of experts (transplant hepatologists, surgeons, pathologist, and psychiatrist) was tasked to formulate clinical questions (in PICO format) that arise during routine management of adult LT recipients. The writing group reviewed the literature, generated guideline recommendations and rated the level of evidence for each recommendation based on the Oxford Center for Evidence-Based Medicine. The group categorized the strength of recommendations based on the level of evidence, risk -benefit ratio, and patient preferences. Conclusion: While robust clinical trial data provide strong guidance on some aspects of graft management in LT such as machine perfusion and immunosuppression efficacy and safety, a significant component of graft management is derived from retrospective cohort data, extrapolation of data from other solid organ transplants, or expert opinion, including the treatment of antibody-mediated rejection. Finally, further investigation is needed to truly optimize the management of the liver allograft, including the prevention of recurrent alcohol-associated, metabolic dysfunction-associated steatotic and immune-mediated liver diseases.
Liver transplantation is lifesaving for patients with end stage liver disease. Similar to the role of transplantation for patients with end stage liver disease, gender affirming hormone therapy (GAHT) can be lifesaving for transgender and gender diverse (TGGD) patients who experience gender dysphoria. However, management of such hormone therapy during the perioperative period is unknown and without clear guidelines. Profound strides can be made in improving care for TGGD patients through gender affirming care and appropriate management of GAHT in liver transplantation. In this article, we call for the transplant community to acknowledge the integral role of GAHT in the care of TGGD liver transplant candidates and recipients. We review the current literature and describe how the transplant community is ethically obligated to address this healthcare gap. We suggest tangible steps that clinicians may take to improve health outcomes for this minoritized patient population.
Background: Better access to direct‐acting antiviral (DAA) therapy has broadened the utilization of hepatitis C virus (HCV) nucleic acid testing (NAT) positive organs with excellent outcomes. However, DAA therapy has been associated with hepatitis B virus (HBV) reactivation.Aim: To determine the risk of HBV transmission or reactivation with utilization of HBV core antibody positive (HBcAb+) and HCV NAT positive (HCV+) organs, which presumably required DAA therapy.Methods: The number of HBcAb+ donors with delineated HCV NAT status was obtained from the Organ Procurement and Transplantation Network (OPTN) database. The number of unexpected HBV infections from transplanted organs adjudicated as “proven” or “probable” transmission was obtained from the OPTN Ad Hoc Disease Transmission Advisory Committee database. A chart review of the donors of “proven” or “probable” cases was conducted.Results: From January 1, 2016, to December 31, 2021, 7735 organs were procured from 3767 HBcAb+ donors and transplanted into 7469 recipients; 545 (14.5%) donors were also HCV+. HBV transmission or reactivation occurred in seven recipients. The rate is not significantly different between recipients of HCV+ (0.18%, 2/1115) and the HCV NAT negative (HCV‐) organs (0.08%, 5/6354) (p = 0.28) or between recipients of HCV+ and HCV‐ livers as well as non‐liver organs. HBV transmission or reactivation occurred within a median of 319 (range, 41–1117) days post‐transplant in the setting of missing, inadequate, or truncated prophylaxis.Conclusion: HBV reactivation associated with DAA therapy for HBcAb+ HCV+ organs is less frequent than reported in the non‐transplant population, possibly due to the common use of HBV prophylaxis in the at‐risk transplant population. image